{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 54 of 92', 'CR845-CLIN3102', '6.5.4.4', 'Vital Signs', 'Vital signs include sitting or semi-recumbent body temperature, heart rate, and blood', 'pressure and will be measured prior to start of dialysis.', 'Measurements will be repeated if a value is out of the reference range due to a technical', 'issue, considered abnormal for the patient, or for other medical concerns. Only the', 'repeated measurement will be recorded.', 'In the event of a clinically significant change in blood pressure and/or heart rate, the', 'Investigator and dialysis staff will evaluate and manage the patient per standard dialysis', \"unit practices with knowledge of the patient's typical blood pressure and heart rate\", 'excursions.', 'Heart rate will be collected at each dialysis; if clinically significant and outside the', 'prespecified visits per schedule of events, the heart rate will be recorded on the relevant', 'CRF page.', '6.5.4.5', 'Electrocardiogram', 'The 12-lead ECGs will be obtained prior to the start of dialysis and will be read locally', 'by the Investigator or qualified designee. Electrocardiograms read by a qualified', 'designee must be endorsed by the Investigator. Clinically significant abnormalities or', 'worsening findings observed after the first dose of study drug will be reported as', 'treatment-emergent adverse events (TEAEs).', '6.5.4.6', 'Clinical Laboratory Tests', 'Blood samples for clinical laboratory tests including hematology, serum chemistry, and', 'serum pregnancy will be taken prior to dialysis and will be analyzed by a central', 'laboratory. Processing and shipment of central laboratory samples will be described in', 'the Laboratory Manual, along with the final list of laboratory tests.', '6.5.4.7', 'Contraception and Pregnancy', 'All females of childbearing potential will have blood samples taken at Screening for', 'serum pregnancy testing. Females are considered to be of childbearing potential unless', 'they are:', 'Surgically sterile (ie, tubal ligation, bilateral oophorectomy, and/or', 'hysterectomy); or', 'Over 55 years of age and have not had a menstrual period in at least 1 year', 'Once they have consented to participate in the study, all women of childbearing potential', 'will be counseled on the importance of avoiding pregnancy and on the need to practice', 'adequate birth control for the duration of the study, from screening until 7 days after the', 'last dose of study drug.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 56 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 55 of 92', 'CR845-CLIN3102', 'Medically acceptable methods of birth control are methods with a failure rate of <1% per', 'year, and include hormonal contraceptives for at least 1 cycle of treatment before study', 'enrollment, an intrauterine device, and double-barrier method (eg, male or female', 'condom, diaphragm).', 'Per inclusion criteria, male patients will agree not to donate sperm after the first dose of', 'study drug until 7 days after the last dose of study drug, and will agree to use a condom', 'with spermicide or abstain from heterosexual intercourse during the study until 7 days', 'after the last dose of study drug. No restrictions are required for a vasectomized male,', 'provided his vasectomy was performed >4 months prior to dosing.', 'Women will be counseled to contact the Investigator or his/her staff immediately if', 'pregnancy is suspected. Males will be instructed to report to the Investigator if their', 'partner becomes pregnant during the study.', 'If a patient becomes pregnant during the Double-blind or Open-label Treatment Periods', 'or within 7 days after the last dose of study drug, the Investigator will immediately', 'discontinue the patient from the study and contact the Sponsor or designee. Diligent', 'efforts will be made to determine the outcome for all pregnancies in the clinical study.', 'Information on the status of the mother and the child will be forwarded to the Sponsor.', 'Generally, follow-up will occur within 6 to 8 weeks following the estimated delivery', 'date. Any premature termination of the pregnancy will be reported. Both maternal and', 'paternal exposure will be collected. For exposure involving the female partner of a male', 'patient, the necessary information must be collected from the patient while respecting the', 'confidentiality of the partner. A pregnancy report will be completed.', '6.5.5', 'Additional Assessments', 'The following additional assessments will be collected during the Double-blind and', 'Open-label Extension Phases:', 'Inflammatory biomarkers', 'Missed dialysis visits', 'ESAs and IV iron', '6.5.5.1', 'Inflammatory Biomarkers', 'Inflammatory biomarkers, such as interleukin (IL)-6, IL-8, and granulocyte', 'macrophage-colony stimulating factor will be measured, as defined in the statistical', 'analysis plan (SAP). A blood sample of sufficient volume to provide for replicate assays', 'of each biomarker will be collected prior to dialysis per the schedules of events.', 'Detailed instructions for biomarker sample collection and processing will be provided in', 'the laboratory manual.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 57 of 95']\n\n###\n\n", "completion": "END"}